Anti-Notch3 antibodies

US9879083B2 · kind B2 · utility

Assignee

• AVEO Pharmaceuticals, Inc. · US

Inventors

• Heidi Okamura · Brookline, US
• Sandra Abbott · Boston, US
• Alisa C. Bell · Bedford, US
• Kelly Kreuter · Arvada, US
• Ronan O'Hagan · Waltham, US
• Samantha Perino · Watertown, US
• Hamid Tissire · Abington, US
• William M. Winston, Jr. · Marlborough, US
• Jeno Gyuris · Lincoln, US

Key dates

• Filing date: Dec 19, 2013
• Grant date: Jan 30, 2018
• Expiry date: Dec 19, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N5/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.